Invion's Phase II Prostate Cancer Trial Yields Promising Results
IVX (IVX) Share Update September 2024 Tuesday 17th
Invion Announces Promising Phase II Prostate Cancer Trial Results
Invion Limited (ASX: IVX) has announced encouraging results from a Phase II prostate cancer trial, highlighting the safety and efficacy of their photosensitiser INV043.
Instant Summary:
- INV043 demonstrated a strong safety profile with no serious adverse events.
- 40% of patients showed a positive response, with 10% achieving complete response.
- 44% of patients had negative PSMA-PET results three months post-treatment.
- Potential for INV043 to be administered systemically in future trials.
- Global prostate cancer market expected to grow to ~US$27.5 billion by 2032.
Trial Overview
Invion Limited (ASX: IVX) has released the results of a Phase II prostate cancer trial using their photosensitiser INV043. The trial, funded by RMW Cho Group Limited (RMWC) and conducted by Scendea Limited, involved administering INV043 sublingually to patients over six treatment cycles.
The trial demonstrated a strong safety profile, with no serious adverse events reported. All side effects were mild, including fever, fatigue, headache, and soreness.
Efficacy Results
In terms of efficacy, 40% of patients showed a positive response to the treatment, with 10% achieving complete regression. Additionally, 44% of patients had negative PSMA-PET results three months post-treatment, indicating a reduction in detectable prostate cancer.
These results suggest that INV043 could offer a safer alternative to conventional prostate cancer treatments, which often come with significant side effects such as urinary incontinence, bowel dysfunction, and erectile dysfunction.
Future Potential
The positive safety and efficacy signals from this trial open the door for further investigation of INV043, including potential systemic administration via sublingual and IV routes. Invion is also exploring combination therapies with immunotherapies to improve response rates further.
The global prostate cancer market is projected to grow significantly, reaching approximately US$27.5 billion by 2032, with an 8.7% compound annual growth rate (CAGR) from 2023 to 2032.
Company Comments
Invion's Executive Chair and CEO, Thian Chew, expressed excitement over the trial results, highlighting the potential for INV043 to become an effective treatment for prostate cancer without the severe side effects associated with conventional treatments.
The trial results are likely to positively impact Invion's stock as investors react to the promising safety and efficacy data. The potential for INV043 to be used systemically in future trials and its application in combination therapies could further enhance its market potential.
Investor Reaction:
Analysts are expected to react positively to the trial results, given the strong safety profile and promising efficacy signals. The potential for INV043 to offer a safer alternative to conventional treatments could drive investor interest.
Conclusion:
Investors should keep an eye on Invion's future announcements regarding further trials and potential combination therapies. The promising results from this Phase II trial suggest that INV043 could become a significant player in the prostate cancer treatment market.